BPC-157 + KPV (Oral Gut Stack)

BPC-157 and KPV are the two peptides most often discussed for gut health, and the oral pairing ("BPC-157 + KPV capsules") has become its own category. The idea is simple. Most gut problems people want help with, such as inflammatory bowel disease, NSAID damage, post-infectious irritation, and the loose label "leaky gut," combine two processes: inflammatory signaling that keeps the lining irritated, and damaged tissue that needs to heal. KPV targets the first. BPC-157 targets the second. Our KPV vs BPC-157 comparison explains the split in detail. In short, KPV is an anti-inflammatory and BPC-157 is a repair peptide, so they are complementary rather than redundant. It helps to separate this stack from the KLOW blend (BPC-157 + TB-500 + GHK-Cu + KPV), because the two serve different purposes. KLOW is an injected four-peptide blend aimed mainly at systemic and musculoskeletal recovery and skin, with gut inflammation as one target among several. The oral BPC-157 + KPV stack targets the gut lumen and lining directly. That distinction matters. For most peptides, swallowing them is a weakness: digestive enzymes break them down and little reaches the bloodstream. For a gut-lining target, oral delivery is the point, because the tissue you want to reach is the one the capsule passes over. This stack is the one context where oral peptide delivery makes mechanistic sense, and where adding injected TB-500 and GHK-Cu would add little. BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) that Predrag Sikiric's group in Zagreb reported deriving from a protective protein in gastric juice. Its developers have long described it as stable in human gastric juice, which is unusual for a peptide and is the main basis for using it orally. In rat studies from that group, BPC-157 given in drinking water healed experimental colitis and colon anastomoses (Klicek et al., 2013), and it protected the gut against NSAID and alcohol injury in many other models. The Croatian company PLIVA developed it for inflammatory bowel disease under the code PL 14736. KPV is the three-amino-acid tail (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone. It keeps the parent hormone's anti-inflammatory activity without the melanocortin-receptor effects that darken skin. Its main oral credential comes from Didier Merlin's lab (Dalmasso et al., Gastroenterology 2008). Intestinal epithelial and immune cells take KPV up through PepT1, a transporter for di- and tripeptides. Nanomolar KPV suppressed NF-κB and MAP-kinase inflammatory signaling, and KPV in drinking water reduced chemically induced colitis in two mouse models. PepT1 normally sits mainly in the small intestine and is switched on in the colon during inflammatory bowel disease, which gives KPV a plausible route to inflamed colon tissue.

The two peptides act through different pathways, which is the main reason to think they could add to each other. KPV works inside the cell. Once PepT1 brings it in, it suppresses NF-κB, the master switch for inflammatory genes such as TNF-α, IL-6, and IL-1β, and dampens MAP-kinase signaling. The net effect is lower inflammatory output from epithelial and immune cells. In mouse colitis models it reduced inflammatory infiltrates, myeloperoxidase activity, and weight loss. A German group (Kannengiesser et al., 2008) showed the benefit held in both chemical and T-cell-transfer colitis, and partly independent of the MC1R melanocortin receptor. BPC-157 works on tissue repair and blood supply. In animal models it upregulates growth-factor signaling (VEGF, EGF), modulates the nitric-oxide system, protects the stomach lining, and restores blood flow to injured gut segments. Its signature effect in the Zagreb models is rapid recovery of local circulation and healing of lesions, anastomoses, and fistulas, rather than suppression of cytokines. Together, the hypothesis is that KPV lowers the inflammatory drive that keeps damaging the lining, while BPC-157 supports the perfusion and tissue repair that rebuild it. That is calm plus rebuild. There is no obvious pharmacological conflict between them. BPC-157 is far too large to be a PepT1 substrate (PepT1 carries only di- and tripeptides), so the two should not compete for the same uptake route, though nobody has measured this. Two caveats temper the logic. First, PepT1 rises in the colon mainly during active inflammation, so KPV's best-supported uptake route is strongest in an actively inflamed colon. In someone with a non-inflamed gut taking it for general optimization, that route may matter less. Second, the two peptides may need to act in different parts of the gut. Much of BPC-157's reputation rests on protecting the stomach and upper GI tract, while KPV's colitis data and its PepT1 rationale center on the colon. A capsule designed to release in one place may not suit the other.

All the evidence for this stack is preclinical. No human trial has tested BPC-157 and KPV together, and a PubMed search as of October 2026 finds no animal study that gives them together either. BPC-157 has a large gastrointestinal animal literature. It covers gastric and duodenal lesions, NSAID-induced damage, cysteamine colitis, ischemic colitis, fistulas, intestinal anastomoses, and short bowel syndrome. Almost all of it comes from one research group in Zagreb, and independent replication is thin. Human gut data are almost nonexistent in the peer-reviewed literature. PLIVA's PL 14736 program ran early-phase trials in inflammatory bowel disease, including ulcerative colitis, in the early 2000s. The originating group describes those trials as showing the peptide was safe, but the efficacy results were never published as full peer-reviewed papers, and the program was abandoned in the mid-2000s. The published human BPC-157 studies are a few tiny, uncontrolled pilots outside the gut. A 2026 Pharmaceutics review (Mateescu et al.) counted fewer than 30 subjects across three uncontrolled pilot studies, none of which used a standardized pharmaceutical preparation. Oral bioavailability is the weakest link for both peptides. The only formal pharmacokinetic study of BPC-157 came from an independent group in China (He et al., Frontiers in Pharmacology 2022). It tested intravenous and intramuscular dosing in rats and dogs and found a plasma half-life under 30 minutes. Bioavailability after intramuscular injection was about 14–19% in rats and 45–51% in dogs, and the peptide was quickly broken into small fragments. Oral dosing was not tested. The claim that BPC-157 survives gastric juice comes from the originating lab, and nobody has measured whether intact, active peptide from a human oral capsule reaches the small intestine or colon. For KPV, PepT1 uptake is well shown in cells and mice, but there is no human pharmacokinetic data at all. Several groups have built nanoparticle and hydrogel delivery systems to get KPV to the inflamed colon (for example, Xiao et al., Molecular Therapy 2017). That effort suggests researchers do not consider plain oral delivery a solved problem. KPV's gastrointestinal evidence is a small number of good-quality mouse studies from at least two unrelated groups: Didier Merlin's lab in the US and its collaborators, and a gastroenterology group in Münster, Germany. That is a modest strength over BPC-157's single-lab concentration. It still adds up to zero completed human trials. There is no human trial in inflammatory bowel disease, no dose-finding, and no comparison with standard therapy. In short, there are two individually plausible gut peptides with coherent rodent data, no human efficacy data for either in gut disease, unmeasured oral bioavailability in humans, and no data on the combination. It is a reasonable hypothesis, not a validated therapy. For diagnosed inflammatory bowel disease it is not a substitute for established treatment.

No combined protocol has been clinically validated. The figures below are what clinicians and peptide communities commonly discuss, taken from community and clinician protocols rather than from human dose-finding trials. They are not a recommendation. Use should be supervised by a clinician, ideally one who knows your gastrointestinal history. Gut symptoms that have not been worked up, especially bleeding, unintended weight loss, nighttime diarrhea, or anemia, need diagnosis before any self-directed peptide trial. BPC-157 (oral): capsules are usually made at 500 mcg or 750 mcg, and the most commonly discussed dose is 500 mcg once or twice daily, often with meals. Many oral products use the arginate salt, marketed as more stable. There is no direct human pharmacokinetic data comparing the arginate and acetate forms. KPV (oral): 200–500 mcg daily is the commonly discussed range, sometimes raised to 1,000 mcg during active flares, taken once or twice daily. Enteric-coated or delayed-release capsules are commonly preferred when the colon is the target, to limit breakdown in the upper GI tract. Combined: some compounders and vendors sell single capsules containing both peptides. That is convenient, but a fixed ratio means the two can't be adjusted separately, and the capsule's release profile sets where in the gut both peptides are delivered. When both are used, a typical commonly discussed cycle is 4–8 weeks followed by a break and reassessment. The more cautious approach is to start one peptide, give it 2–3 weeks, then add the other, so that any change can be traced to its source. Track a symptom and stool diary from baseline. If you have diagnosed inflammatory bowel disease, track objective markers your gastroenterologist already follows, such as fecal calprotectin and CRP, rather than relying on how you feel.